| scholarly article | Q13442814 |
| P50 | author | Burkhardt Seifert | Q37371167 |
| Lorenz Leitner | Q41685469 | ||
| Matthias Walter | Q56941298 | ||
| P2093 | author name string | Marc P Schneider | |
| Thomas M Kessler | |||
| Ulrich Mehnert | |||
| Jure Tornic | |||
| Stephanie C Knüpfer | |||
| Ulla Sammer | |||
| P2860 | cites work | Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America | Q28273894 |
| Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury | Q33874910 | ||
| Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults | Q34394950 | ||
| The National Spina Bifida Patient Registry: profile of a large cohort of participants from the first 10 clinics | Q35951274 | ||
| The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines | Q36946338 | ||
| Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. | Q37281713 | ||
| Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures | Q37903751 | ||
| An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders | Q38163218 | ||
| Lower urinary tract dysfunction in the neurological patient: clinical assessment and management | Q38525503 | ||
| More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned. | Q39829403 | ||
| Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology | Q41035239 | ||
| Neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury: long-term urodynamic findings | Q41043527 | ||
| An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity | Q44539406 | ||
| Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results | Q46349100 | ||
| Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims database | Q46560975 | ||
| Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity | Q46586297 | ||
| European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity | Q47892069 | ||
| The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients | Q48279466 | ||
| Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment | Q48347197 | ||
| Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial | Q48621733 | ||
| Controversies in antibiotic prophylaxis in urology. | Q51699225 | ||
| International Continence Society guidelines on urodynamic equipment performance. | Q53097281 | ||
| Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. | Q53155089 | ||
| Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. | Q53315918 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| Is there a direct antimicrobial effect of botulinum neurotoxin type A? | Q54330559 | ||
| Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections | Q81096770 | ||
| Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study | Q81833229 | ||
| Botulinum toxin injections into the detrusor | Q82170616 | ||
| Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis | Q95480937 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | botulinum toxin type A | Q4095199 |
| P304 | page(s) | 33197 | |
| P577 | publication date | 2016-09-12 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity | |
| P478 | volume | 6 |
| Q90630914 | Safety of Intradetrusor OnabotulinumtoxinA (BTX-A) Injection in the Asymptomatic Patient With a Positive Urine Dip | cites work | P2860 |
Search more.